ClinicalTrials.gg
Not yet recruitingNCT06585579ORIGYNEUpdated Sep 5, 2024

The Effect of Mucogyne® Ovule on Wound Healing (ORIGYNE)

An interventional study of Mucogyne Ovule in Cervicovaginitis, sponsored by Biocodex. Not yet recruiting at 3 sites in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-05.

Sponsored by Biocodex · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This clinical investigation is a post-market clinical follow-up performed to confirm the performance and safety of the Mucogyne® ovule medical device in promoting the process of wound healing, when used in accordance with its approved labelling, in the context of local cervicovaginal surgery.

02

Conditions studied

  • Cervicovaginitis
03

In context

Lead sponsor

Biocodex is the lead sponsor of 19 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult women who had undergone localized surgery (laser or loop electrosurgical excision procedure (LEEP) conization) for cervical or vaginal dysplasia,
  2. Is able to understand the study related information and to give a written ,
  3. Has signed the informed consent form before beginning any study procedure,
  4. Has no condition that may interfere with the study assessments,
  5. Agrees not to use other vaginal products than those planned in the study protocol, during participation in the study,
  6. Is able to comply with protocol requirements and respect the conditions of the study,
  7. Affiliated to the Social Security system.

Exclusion criteria

Exclusion Criteria:

  1. Previous vaginal surgery within the year preceding the inclusion in the study,
  2. Known to any of the medical device ingredients,
  3. Patient with local infectious lesions in the area to be repaired.
  4. Patient who had used anti-inflammatory drugs (regular intake) or anticoagulants during the month preceding the inclusion in the study,
  5. Patient who had a history of diseases known to disturb wound healing (e.g. systemic, heart, and renal diseases, coagulation disorders, immunedeficiency, connective tissue disorders, diabetes, anemia (with level \< 9 g/dl) and hemophilia),
  6. treatment,
  7. Heavy cigarettes smoker (i.e., more than 15 cigarettes or equivalent/day, according to the patient and their documented records),
  8. Patients under judicial protection or under guardianship and patients deprived of freedom,
  9. Has any other severe chronic or acute medical or psychiatric condition that in the judgment of the Investigator, could interfere with the study assessments.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
144 participants (estimated)

Study arms

  • Experimental
    Mucogyne group

    For each eligible patient, the study will consist of: * A Screening/Inclusion visit * A treatment period (application of the medical device Mucogyne® ovule) for 21 days * An End Of Study visit (Day 21 (+10) after surgery)

    Device: Mucogyne Ovule

  • No intervention
    Control group

    standard of care e.i no treatment

Interventions

  • DeviceMucogyne Ovule

    In Mucogyne group, patient will receive 2 boxes of Mucogyne® ovule. 24 hours after intervention, the patient will apply Mucogyne® ovule, 1 ovule per day for 10 days, to be repeated as needed (for practices' homogenisation, after the 10th day, it is recommended to apply one ovule every second day, until EOS visit)

06

What researchers measure

Primary outcomes

  1. To confirm the performance of Mucogyne® ovule in wound healing promotion

    The primary endpoint is a composite endpoint derived with the following criteria: * Inflammation evaluated with a 5-point scale (none, mild, moderate, severe, very severe) and not assessed, * Edema evaluated with a 5-point scale (none, mild, moderate, severe, very severe) and not assessed, * Abrasion evaluated with a 5-point scale (none, mild, moderate, severe, very severe) and not assessed, * Coalescence evaluated with a 3-point scale (none, partial, total) and not assessed. * Opening of the cervix (only for cervical wound) evaluated with a 4-point scale (closed, slightly open, open, gaping) and not assessed.

    Time frame: Day 0 to day 21(+10)

Secondary outcomes

  1. To assess the aspect of the epithelium 3(+1) weeks after surgery

    Criteria assessing the aspect of the epithelium (such as presence of mucosa, stroma, presence and quality of mucus, opening of the cervix, presence or absence of inflammation, edema, vulvo-vaginal abrasions, coalescence, adherence, leucorrhoea and bleeding at contact)

    Time frame: Day 0 to day 21(+10)

  2. To assess the performance of Mucogyne® ovule in symptoms relief

    Vaginal symptoms (dryness, itching, burning, discharge) will be assessed by the patient using a 4-point scale (1 = absent, 2 = mild, 3 = moderate, 4 = severe) at 3 (+1) weeks after surgery

    Time frame: Day 0 to day 21(+10)

  3. To assess the performance of Mucogyne® ovule in reducing postoperative side effects and complications

    Postoperative side-effects (i.e. postoperative bleeding, infection and impairment of daily activities, etc.) will be assessed using a questionnaire. For the assessment of hemorrhage, the amounts of bleeding will be checked with a pictorial blood assessment chart.

    Time frame: Day 0 to day 21(+10)

  4. To assess change in clinical status

    Change in clinical status will be assessed by the Investigator using Clinical Global Impressions scale, (CGI) at 3(+1) weeks after surgery

    Time frame: Day 0 to day 21(+10)

  5. To assess compliance with the Medical Device use

    Compliance with the Medical Device use will be assessed by number of days of use

    Time frame: Day 0 to day 21(+10)

  6. To assess the safety of Mucogyne® ovule

    Number, nature and characteristics of any incident reported: incidence, seriousness, severity, resolution

    Time frame: Day 0 to day 21(+10)

07

Study locations

3 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2024; primary completion for Aug 2025, 10 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2024
First posted
Sep 5, 2024
StartEst.
Oct 2024
Primary completionEst.
Aug 2025
CompletionEst.
Nov 2025
Last update
Sep 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06585579
Lead sponsor
Biocodex
Responsible party
Sponsor
First posted
Sep 5, 2024
Start date
Oct 2024 (estimated)
Primary completion
Aug 2025 (estimated)
Completion
Nov 2025 (estimated)
Last update
Sep 5, 2024

Study contacts

Gaëlle MARIAULE
Contact
g.mariaule@biocodex.fr
+33 3 44 86 75 97
Oana BERNARD, MD
study director · Chief Scientific Officer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion